ARID1A and ovarian clear cell cancer: The highest ARID1A mutation rates are found in ovarian clear cell carcinoma (OCCC) and endometroid ovarian carcinoma (Table 2) suggesting its role in type I OC development and the potential for ARID1A’s use as a gynecologic cancer biomarker.